Scientific publications

Last update: March 21th, 2019.

Bibliographic references

 

Scientific publications – Diabetes

  1. Costa, B., Barrio, F., Piñol, J. L., Cabré, J. J., Mundet, X., … Solà-Morales, O. (2013). Shifting from glucose diagnosis to the new HbA1c diagnosis reduces the capability of the Finnish Diabetes Risk Score (FINDRISC) to screen for glucose abnormalities within a real-life primary healthcare preventive strategy. BMC Medicine, 11(1). doi:10.1186/1741-7015-11-45
  2. D’ Emden, M. C., Shaw, J. E., Jones, G. R., & Cheung, N. W. (2015). Guidance concerning the use of glycated haemoglobin (HbA1c) for the diagnosis of diabetes mellitus. The Medical Journal of Australia, 203(2), 89–90. doi:10.5694/mja15.00041
  3. Fonseca, V., Inzucchi, S. E., & Ferrannini, E. (2009). Redefining the Diagnosis of Diabetes Using Glycated Hemoglobin. Diabetes Care, 32(7), 1344–1345. doi:10.2337/dc09-9034
  4. Goldenberg, R. M., Cheng, A. Y. Y., Punthakee, Z., & Clement, M. (2011). Use of Glycated Hemoglobin (A1C) in the Diagnosis of Type 2 Diabetes Mellitus in Adults. Canadian Journal of Diabetes, 35(3), 247–249. doi:10.1016/s1499-2671(11)53006-0
  5. Incani, M., Sentinelli, F., Perra, L., Pani, M. G., Porcu, M., Lenzi, A., … Baroni, M. G. (2014). Glycated hemoglobin for the diagnosis of diabetes and prediabetes: Diagnostic impact on obese and lean subjects, and phenotypic characterization. Journal of Diabetes Investigation, 6(1), 44–50. doi:10.1111/jdi.12241
  6. Jones, D., Scharfenberg, B., Perkins, J., Childers, K., Dogbey, G. Y., & Shubrook, J. H. (2016). Glycated Hemoglobin Testing to Identify Undiagnosed Diabetes Mellitus in the Inpatient Setting. The Journal of the American Osteopathic Association, 116(6), 350. doi:10.7556/jaoa.2016.075
  7. Khalafallah, A., Phuah, E., Al-Barazan, A. M., Nikakis, I., Radford, A., Clarkson, W., … Corbould, A. (2016). Glycosylated haemoglobin for screening and diagnosis of gestational diabetes mellitus. BMJ Open, 6(4), e011059. doi:10.1136/bmjopen-2016-011059
  8. Kirkman, M. S., & Kendall, D. M. (2010). Hemoglobin A1c to Diagnose Diabetes: Why the Controversy over Adding a New Tool? Clinical Chemistry, 57(2), 255–257. doi:10.1373/clinchem.2010.148213
  9. Kumar, P. R., Bhansali, A., Ravikiran, M., Bhansali, S., Dutta, P., Thakur, J. S., … Walia, R. (2010). Utility of Glycated Hemoglobin in Diagnosing Type 2 Diabetes Mellitus: A Community-Based Study. The Journal of Clinical Endocrinology & Metabolism, 95(6), 2832–2835. doi:10.1210/jc.2009-2433
  10. Sherwani, S. I., Khan, H. A., Ekhzaimy, A., Masood, A., & Sakharkar, M. K. (2016). Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients. Biomarker Insights, 11, BMI.S38440. doi:10.4137/bmi.s38440
  11. Vega-Vázquez, M. A., Ramírez-Vick, M., Muñoz-Torres, F. J., González-Rodríguez, L. A., & Joshipura, K. (2017). Comparing glucose and hemoglobin A1c diagnostic tests among a high metabolic risk Hispanic population. Diabetes/Metabolism Research and Reviews, 33(4), e2874. doi:10.1002/dmrr.2874

Scientific publications – Hyperuricemia and Gout

  1. BARBER, C. (2012). Gout: Diagnosis and Management of Gouty Arthritis and Hyperuricemia. The Journal of Rheumatology, 39(2), 454–454. doi:10.3899/jrheum.110323
  2. Doghramji, P. P., & Wortmann, R. L. (2012). Hyperuricemia and Gout: New Concepts in Diagnosis and Management. Postgraduate Medicine, 124(6), 98–109. doi:10.3810/pgm.2012.11.2616
  3. Kuwabara, M. (2016). Hyperuricemia, Cardiovascular Disease, and Hypertension. Pulse, 3(3-4), 242–252. doi:10.1159/000443769
  4. Kuwabara, M., Niwa, K., Hisatome, I., Nakagawa, T., Roncal-Jimenez, C. A., Andres-Hernando, A., … Johnson, R. J. (2017). Asymptomatic Hyperuricemia Without Comorbidities Predicts Cardiometabolic DiseasesNovelty and Significance. Hypertension, 69(6), 1036–1044. doi:10.1161/hypertensionaha.116.0899
  5. Li, Q., Li, X., Kwong, J. S.-W., Chen, H., Sun, X., Tian, H., & Li, S. (2017). Diagnosis and treatment for hyperuricaemia and gout: a protocol for a systematic review of clinical practice guidelines and consensus statements. BMJ Open, 7(6), e014928. doi:10.1136/bmjopen-2016-014928
  6. Mazza, A., & Lenti, S. (2016). PS 05-53 THE ASYMPTOMATIC HYPERURICEMIA DIAGNOSIS IN THE REAL WORLD. Journal of Hypertension, 34, e155. doi:10.1097/01.hjh.0000500313.85431.3c
  7. Song, P., Wang, H., Xia, W., Chang, X., Wang, M., & An, L. (2018). Prevalence and correlates of hyperuricemia in the middle-aged and older adults in China. Scientific Reports, 8(1). doi:10.1038/s41598-018-22570-9
  8. Shekelle, P. G., Newberry, S. J., FitzGerald, J. D., Motala, A., O’Hanlon, C. E., Tariq, A., … Shanman, R. (2016). Management of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline. Annals of Internal Medicine, 166(1), 37. doi:10.7326/m16-0461

Scientific publications – Liver Function

  1. Ahmed, Z., Ahmed, U., Walayat, S., Ren, J., Martin, D. K., Moole, H., … Dhillon, S. (2018). Liver function tests in identifying patients with liver disease. Clinical and Experimental Gastroenterology, Volume 11, 301–307. doi:10.2147/ceg.s160537
  2. Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., … Sanyal, A. J. (2017). The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 67(1), 328–357. doi:10.1002/hep.29367
  3. Limdi, J. K. (2003). Evaluation of abnormal liver function tests. Postgraduate Medical Journal, 79(932), 307–312. doi:10.1136/pmj.79.932.307
  4. Newsome, P. N., Cramb, R., Davison, S. M., Dillon, J. F., Foulerton, M., Godfrey, E. M., … Yeoman, A. (2017). Guidelines on the management of abnormal liver blood tests. Gut, 67(1), 6–19. doi:10.1136/gutjnl-2017-314924
  5. Targher, G., & Byrne, C. D. (2015). Circulating Markers of Liver Function and Cardiovascular Disease RiskSignificance: Figure. Arteriosclerosis, Thrombosis, and Vascular Biology, 35(11), 2290–2296. doi:10.1161/atvbaha.115.305235
  6. Thapa, B. R., & Walia, A. (2007). Liver function tests and their interpretation. The Indian Journal of Pediatrics, 74(7), 663–671. doi:10.1007/s12098-007-0118-7
  7. Wolf, P. L. (1999). Biochemical diagnosis of liver disease. Indian Journal of Clinical Biochemistry, 14(1), 59–90. doi:10.1007/bf02869152
  8. Zhang, L., Zhou, P., Meng, Z., Pang, C., Gong, L., Zhang, Q., … Song, K. (2018). Infectious mononucleosis and hepatic function. Experimental and Therapeutic Medicine. doi:10.3892/etm.2018.5736

Scientific publications – Renal Function

  1. Berhane, A. M., Weil, E. J., Knowler, W. C., Nelson, R. G., & Hanson, R. L. (2011). Albuminuria and Estimated Glomerular Filtration Rate as Predictors of Diabetic End-Stage Renal Disease and Death. Clinical Journal of the American Society of Nephrology, 6(10), 2444–2451. doi:10.2215/cjn.00580111
  2. Chapter 1: Definition and classification of CKD. (2013). Kidney International Supplements, 3(1), 19–62. doi:10.1038/kisup.2012.64
  3. Eckardt, K.-U., & Kasiske, B. L. (2009). KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Foreword. Kidney International, 76, S1–S2. doi:10.1038/ki.2009.188
  4. Fraser, S., & Blakeman, T. (2016). Chronic kidney disease: identification and management in primary care. Pragmatic and Observational Research, Volume 7, 21–32. doi:10.2147/por.s97310
  5. Gómez Marcos MA1, Rodríguez Sánchez E, Recio Rodríguez JI, Martín Cantera M, Ramos Blanes R, García Ortiz L. Diferencias de la ecuación CKD-EPI con la de MDRD para la estimación del filtrado glomerular en pacientes hipertensos. Nefrologia. 2010;30(4):458-62. doi: 10.3265/Nefrologia.pre2010.Mar.10321.
  6. GOROSTIDI M, SANTAMARÍA R, ALCÁZAR R, FERNÁNDEZ-FRESNEDO G, GALCERÁN JM, GOICOECHEA M, OLIVERAS A, PORTOLÉS J, RUBIO E, SEGURA J, ARANDA P, DE FRANCISCO ALM, DEL PINO MD, DEL PINO F, GÓRRIZ JL, LUÑO J, MARÍN R, MARTÍNEZ I, MARTÍNEZ-CASTELAO A, ORTE LM, QUEREDA C, RODRÍGUEZ-PÉREZ JC, RODRÍGUEZ M, RUILOPE LM. Documento de la Sociedad Española de Nefrología sobre las guías KDIGO para la evaluación y el tratamiento de la enfermedad renal crónica. Nefrología 2014;34(3): 302-316. doi:10.3265/Nefrologia.pre2014.Feb.12464
  7. Heras, M., Fernández-Reyes, M. J., Guerrero, M. T., & Sánchez, R. (2011). ¿Qué aporta la nueva ecuación CKD-EPI en la estimación del filtrado glomerular en los ancianos? Revista Española de Geriatría y Gerontología, 46(3), 176–177. doi:10.1016/j.regg.2010.12.004
  8. Hirst, J. A., Montes, M. D. V., Taylor, C. J., Ordóñez-Mena, J. M., Ogburn, E., Sharma, V., … Hobbs, F. R. (2018). Impact of a single eGFR and eGFR-estimating equation on chronic kidney disease reclassification: a cohort study in primary care. British Journal of General Practice, 68(673), e524–e530. doi:10.3399/bjgp18x697937
  9. Hoefield, R. A., Kalra, P. A., Baker, P. G., Sousa, I., Diggle, P. J., Gibson, M. J., … New, J. P. (2010). The use of eGFR and ACR to predict decline in renal function in people with diabetes. Nephrology Dialysis Transplantation, 26(3), 887–892. doi:10.1093/ndt/gfq526
  10. Inker, L. A., Schmid, C. H., Tighiouart, H., Eckfeldt, J. H., Feldman, H. I., Greene, T., … Levey, A. S. (2012). Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin C. New England Journal of Medicine, 367(1), 20–29. doi:10.1056/nejmoa1114248
  11. Levey, A. S., & Stevens, L. A. (2010). Estimating GFR Using the CKD Epidemiology Collaboration (CKD-EPI) Creatinine Equation: More Accurate GFR Estimates, Lower CKD Prevalence Estimates, and Better Risk Predictions. American Journal of Kidney Diseases, 55(4), 622–627. doi:10.1053/j.ajkd.2010.02.337
  12. MacIsaac, R. J., Ekinci, E. I., Premaratne, E., Lu, Z. X., Seah, J., Li, Y., … Jerums, G. (2015). The Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation does not improve the underestimation of Glomerular Filtration Rate (GFR) in people with diabetes and preserved renal function. BMC Nephrology, 16(1). doi:10.1186/s12882-015-0196-0
  13. Matsushita, K., Mahmoodi, B. K., Woodward, M., Emberson, J. R., Jafar, T. H., Jee, S. H., … Chronic Kidney Disease Prognosis Consortium, for the. (2012). Comparison of Risk Prediction Using the CKD-EPI Equation and the MDRD Study Equation for Estimated Glomerular Filtration Rate. JAMA, 307(18). doi:10.1001/jama.2012.3954
  14. Park, J. I., Baek, H., Kim, B. R., & Jung, H. H. (2017). Comparison of urine dipstick and albumin:creatinine ratio for chronic kidney disease screening: A population-based study. PLOS ONE, 12(2), e0171106. doi:10.1371/journal.pone.0171106
  15. Sandilands, E., Dhaun, N., Dear, J., & Webb, D. (2013). Measurement of renal function in patients with chronic kidney disease. British Journal of Clinical Pharmacology, n/a–n/a. doi:10.1111/bcp.12198
  16. Schwandt, A., Denkinger, M., Fasching, P., Pfeifer, M., Wagner, C., Weiland, J., … Holl, R. W. (2017). Comparison of MDRD, CKD-EPI, and Cockcroft-Gault equation in relation to measured glomerular filtration rate among a large cohort with diabetes. Journal of Diabetes and Its Complications, 31(9), 1376–1383. doi:10.1016/j.jdiacomp.2017.06.016
  17. Van den Brand, J. A. J. G., van Boekel, G. A. J., Willems, H. L., Kiemeney, L. A. L. M., den Heijer, M., & Wetzels, J. F. M. (2011). Introduction of the CKD-EPI equation to estimate glomerular filtration rate in a Caucasian population. Nephrology Dialysis Transplantation, 26(10), 3176–3181. doi:10.1093/ndt/gfr003

Scientific publications – Prostate Function

  1. Antunes, A. A., Srougi, M., Dall’Oglio, M. F., Vicentini, F., Paranhos, M., & Freire, G. C. (2008). The Role of BPH, Lower Urinary Tract Symptoms, and PSA Levels on Erectile Function of Brazilian Men Who Undergo Prostate Cancer Screening. The Journal of Sexual Medicine, 5(7), 1702–1707. doi:10.1111/j.1743-6109.2007.00713.x
  2. Catalona, W. J., Partin, A. W., Slawin, K. M., Brawer, M. K., Flanigan, R. C., Patel, A., … Southwick, P. C. (1998). Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease. JAMA, 279(19), 1542. doi:10.1001/jama.279.19.1542
  3. Eleazu, C., Eleazu, K., & Kalu, W. (2017). Management of Benign Prostatic Hyperplasia: Could Dietary Polyphenols Be an Alternative to Existing Therapies? Frontiers in Pharmacology, 8. doi:10.3389/fphar.2017.00234
  4. Fowke, J. H., Koyama, T., Fadare, O., & Clark, P. E. (2016). Does Inflammation Mediate the Obesity and BPH Relationship? An Epidemiologic Analysis of Body Composition and Inflammatory Markers in Blood, Urine, and Prostate Tissue, and the Relationship with Prostate Enlargement and Lower Urinary Tract Symptoms. PLOS ONE, 11(6), e0156918. doi:10.1371/journal.pone.0156918
  5. Huang, Y., Li, Z.-Z., Huang, Y.-L., Song, H.-J., & Wang, Y.-J. (2018). Value of free/total prostate-specific antigen (f/t PSA) ratios for prostate cancer detection in patients with total serum prostate-specific antigen between 4 and 10 ng/mL. Medicine, 97(13), e0249. doi:10.1097/md.0000000000010249
  6. Kaynar, M., Yildirim, M. E., Gul, M., Kilic, O., Ceylan, K., & Goktas, S. (2015). Benign prostatic hyperplasia and prostate cancer differentiation via platelet to lymphocyte ratio. Cancer Biomarkers, 15(3), 317–323. doi:10.3233/cbm-150458
  7. Loeb, S., & Catalona, W. J. (2008). What to Do with an Abnormal PSA Test. The Oncologist, 13(3), 299–305. doi:10.1634/theoncologist.2007-0139
  8. Martins, A. C. P., Rodrigues Jr, A. A., Reis, R. B., Bovo, T. B., Suaid, H. J., Cologna, A. J., … Paschoalin, E. L. (2003). Free PSA and prostate volume on the diagnosis of prostate carcinoma. Acta Cirurgica Brasileira, 18(suppl 5), 22–24. doi:10.1590/s0102-86502003001200008
  9. Mione, R., Barioli, P., Barichello, M., Zattoni, F., Prayer-Galetti, T., Plebani, M., … Gion, M. (1998). Prostate Cancer Probability after Total PSA and Percent Free PSA Determination. The International Journal of Biological Markers, 13(2), 77–86. doi:10.1177/172460089801300203
  10. Mobley, D., Feibus, A., & Baum, N. (2015). Benign prostatic hyperplasia and urinary symptoms: Evaluation and treatment. Postgraduate Medicine, 127(3), 301–307. doi:10.1080/00325481.2015.1018799
  11. Phiri-Ramongane, B., & Khine, A. (2018). Performance of free prostate-specific antigen ratio in differentiating between prostatic cancer and benign prostatic lesions at a referral hospital in South Africa. South African Family Practice, 60(4), 103–106. doi:10.1080/20786190.2018.1432139
  12. Prcić, Alden & Begic, Edin & Hiros, Mustafa. (2016). Actual Contribution of Free to Total PSA Ratio in Prostate Diseases Differentiation. Medical Archives. 70. 288-292. 10.5455/medarh.2016.70.288-292.
  13. Pruthi, R. S. (2001). The dynamics of prostate-specific antigen in benign and malignant diseases of the prostate. BJU International, 86(6), 652–658. doi:10.1046/j.1464-410x.2000.00870.x
  14. Schenk, J. M., Kristal, A. R., Arnold, K. B., Tangen, C. M., Neuhouser, M. L., Lin, D. W., … Thompson, I. M. (2011). Association of Symptomatic Benign Prostatic Hyperplasia and Prostate Cancer: Results from the Prostate Cancer Prevention Trial. American Journal of Epidemiology, 173(12), 1419–1428. doi:10.1093/aje/kwq493
  15. Woodard, T. J., Manigault, K. R., McBurrows, N. N., Wray, T. L., & Woodard, L. M. (2016). Management of Benign Prostatic Hyperplasia in Older Adults. The Consultant Pharmacist, 31(8), 412–424. doi:10.4140/tcp.n.2016.412